

RESEARCH

Open Access



# The role of human Metapneumovirus genetic diversity and nasopharyngeal viral load on symptom severity in adults

Xiang Yong Oong<sup>1</sup>, Jack Bee Chook<sup>2</sup>, Kim Tien Ng<sup>1</sup>, Wei Zhen Chow<sup>1</sup>, Kok Gan Chan<sup>3</sup>, Nik Sherina Hanafi<sup>4</sup>, Yong Kek Pang<sup>1</sup>, Yoke Fun Chan<sup>5</sup>, Adebba Kamarulzaman<sup>1</sup> and Kok Keng Tee<sup>2,5\*</sup>

## Abstract

**Background:** Human metapneumovirus (HMPV) is established as one of the causative agents of respiratory tract infections. To date, there are limited reports that describe the effect of HMPV genotypes and/or viral load on disease pathogenesis in adults. This study aims to determine the role of HMPV genetic diversity and nasopharyngeal viral load on symptom severity in outpatient adults with acute respiratory tract infections.

**Methods:** Severity of common cold symptoms of patients from a teaching hospital was assessed by a four-category scale and summed to obtain the total symptom severity score (TSSS). Association between the fusion and glycoprotein genes diversity, viral load (quantified using an improved RT-qPCR assay), and symptom severity were analyzed using bivariate and linear regression analyses.

**Results:** Among 81/3706 HMPV-positive patients, there were no significant differences in terms of demographics, number of days elapsed between symptom onset and clinic visit, respiratory symptoms manifestation and severity between different HMPV genotypes/sub-lineages. Surprisingly, elderly patients ( $\geq 65$  years old) had lower severity of symptoms (indicated by TSSS) than young and middle age adults ( $p = 0.008$ ). Nasopharyngeal viral load did not correlate with nor predict symptom severity of HMPV infection. Interestingly, at 3–5 days after symptom onset, genotype A-infected patients had higher viral load compared to genotype B (4.4 vs. 3.3  $\log_{10}$  RNA copies/ $\mu\text{l}$ ) ( $p = 0.003$ ).

**Conclusions:** Overall, HMPV genetic diversity and viral load did not impact symptom severity in adults with acute respiratory tract infections. Differences in viral load dynamics over time between genotypes may have important implications on viral transmission.

**Keywords:** Human metapneumovirus (HMPV), Genetic diversity, Viral load, Symptom severity, Acute respiratory tract infection

## Background

Human metapneumovirus (HMPV) is a negative-stranded RNA virus classified in the *Pneumoviridae* family [1]. HMPV infections are commonly associated with mild respiratory symptoms, but severe cough, bronchiolitis and pneumonia have also been reported, sometimes accompanied by high fever, myalgia and vomiting [2]. Several

risk factors associated with more severe disease due to HMPV infection in adults have been identified, which include patients with pulmonary disease or congestive heart disease, healthy elderly patients with age over 65 years old, long term stay in hospital care facilities and immunocompromised patients [3].

Previous reports had attempted to associate the genetic diversity of HMPV, which are classified as genotypes A and B (with further classification into sub-lineages - A1, A2a, A2b, B1 and B2) [4] with disease severity [5–7]. For instances, it was found that HMPV genotype A infection in children caused more severe illnesses (e.g. higher risk of

\* Correspondence: [k2tee@um.edu.my](mailto:k2tee@um.edu.my)

<sup>2</sup>School of Healthcare and Medical Sciences, Sunway University, 47500 Kuala Lumpur, Selangor, Malaysia

<sup>5</sup>Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Full list of author information is available at the end of the article



pneumonia and oxygen saturation < 90%, need for hospitalization, and longer stay of intensive care unit) compared with genotype B infection [7]. In contrast, some studies reported that genotype B infection was one of the risk factors for severe disease [5] with more pathological signs on chest X-ray compared with genotype A infection [6]. Furthermore, some associations remain debatable as several studies found no direct correlation between HMPV genotypes and severity of illness [8–10]. On the other hand, apart from viral genetic diversity, HMPV viral load was recognized as a risk factor associated with more severe disease outcome leading to hospitalization [11, 12].

Although HMPV genetic diversity continues to be described and linked with disease severity in hospitalized children [6], pediatrics [13], elderly adults [10] and immunocompromised patients [3], reports that address this association have been limited in the adult outpatient settings. A recent study which showed that HMPV can also cause respiratory outbreaks in adults [14] highlights the fact that adults may play a role in the transmission and evolutionary dynamics of the virus, and more severe disease could occur in adults during an outbreak.

Hence, in this study, we sought to investigate the possible linkage of genetic diversity on symptom severity in adult outpatients with HMPV infection presenting acute upper respiratory tract infections (URTI) [15]. Using an improved molecular assay for viral load quantification, we also assessed the correlation of HMPV viral load in nasopharyngeal specimens on symptom severity.

## Methods

### Sample collection, symptom severity assessment, and HMPV genotyping

A total of 3706 consenting adult outpatients who presented with symptoms of acute URTI for not more than two weeks were recruited at the Primary Care Clinic of University of Malaya Medical Centre (UMMC) in Kuala Lumpur, Malaysia between February 2012 and May 2014. During enrollment, participants were interviewed to determine their demographics (age, gender and ethnicity), estimated number of days elapsed between symptom onset and clinic visit or enrollment date, and the presence and severity of common cold symptoms [16, 17]. The common cold symptoms assessed were sneezing, nasal discharge, nasal congestion, cough, sore throat, hoarseness of voice, headache and muscle ache. The severity of each symptom was then rated by a standardized four-category ordinal scale previously reported [16–19]: none (0), mild (1), moderate (2) and severe (3). The symptom ratings were summed to create a total symptom severity score (TSSS) for each participant with a maximum points of 24 from eight symptoms [20], in which greater symptom severity was indicated by a higher score.

Nasopharyngeal swabs were collected from the patients and transferred to the laboratory in universal transport media (Copan Diagnostics, California, USA). Total nucleic acid purification was performed using the NucliSENS easyMAG automated nucleic acid extraction system (bioMérieux, Marcy l’Etoile, France) according to manufacturer’s protocol [21]. The xTAG Respiratory Virus Panel (RVP) FAST multiplex RT-PCR assay (Luminex Molecular, Toronto, Canada) and Luminex’s proprietary Universal Tag sorting system on Luminex 200 IS platform (Luminex Corp., Austin, Texas, USA) were used to detect HMPV in the samples [22]. The genotype of HMPV-positive samples was first determined by performing amplification and sequencing of the fusion (*F*) and attachment (*G*) genes as previously described [15]. This was followed by phylogenetic tree reconstruction using the maximum-likelihood (ML) method which was heuristically inferred using subtree pruning and regrafting and nearest neighbor interchange algorithms with a general time-reversible (GTR) nucleotide substitution model, a proportion of invariant sites (+I) and four categories of gamma rate heterogeneity (+ $\Gamma_4$ ), which were implemented in PAUP version 4.0 [23]. Kimura’s two-parameter model with a reliability of branching order analyzed by bootstrap replicates of 1000 was used.

### HMPV viral load quantification

For improved quantification of HMPV RNA in the nasopharyngeal specimens, a comprehensive and updated list of reference genomes was used to design a quantitative one-step reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) assay. Newly designed primer pair and a fluorescent probe targeting the highly conserved *M2* gene [24] of HMPV were developed based on a set of global HMPV complete genomes representing all genotypes A1, A2a, A2b, B1 and B2 ( $n = 135$ ) available in GenBank (retrieved on 31 January 2016). The sequences were codon-aligned using the web-based multiple sequence alignment program MAFFT [25] to look for conserved regions of the complete genome. Highly conserved forward primer, reverse primer and the probe with a coverage of 99.3, 100, and 99.3%, respectively, based on the alignment of the global reference sequence (Additional file 1), were designed using the Primer Express Software v2.0 (Applied Biosystems, California, USA). With reference to the nucleotide numbering of NC\_004148 (HMPV reference strain), the forward primer (designated as 4730f), reverse primer (4919r) and probe (4796fp) spanned the genetic regions corresponding to nucleotide positions 4730–4754, 4919–4893 and 4796–4814 nt, respectively. The probe was labeled with the 6-fluorescein amidite (FAM) at the 5’ end, and the non-fluorescent

quencher (NFQ) and minor groove binder (MGB) at the 3'-end. A synthetic single-stranded RNA oligonucleotide with a randomly generated sequence was designed and used as internal control (IC) to check for potential PCR inhibition. The unique IC sequence (5'-ACATCGTAA GGCTCCATGCAAATATGAAGATAGAATGCTTAGGA CCATCAGCGAAACTCTACAATAATATCAGGCGCAG GCAGAGAAGTA-3') showed < 10% similarity with any published sequence in the GenBank (data not shown). The IC was flanked by sequences similar to the primer binding site of the newly designed HMPV primer set, with a unique non-HMPV probe designed for the IC (VIC-5'-TTAG GACCATCAGCGAAAC-3'-NFQ-MGB). In a single reaction, 0.2  $\mu$ l of reverse transcriptase (40 U), 10  $\mu$ l of 2 $\times$  One-Step SensiFAST Probe Lo-ROX mix (Bioline, London, UK), 0.8  $\mu$ l of each primer (20  $\mu$ M), 1  $\mu$ l of each probe (10  $\mu$ M), and  $6.0 \times 10^3$  RNA copies/ $\mu$ l of IC in a final volume of 20  $\mu$ l. The optimized thermal cycling profile used was as follows: reverse transcription at 48  $^{\circ}$ C for 8 min, initial denaturation at 95  $^{\circ}$ C for 2 min, followed by 40 cycles of 97  $^{\circ}$ C for 2 s, and 60  $^{\circ}$ C for 20s. The thermal cycling period of the assay was short, in which viral load quantification can be accomplished within approximately 50 min in a single run. A synthetic DNA oligonucleotide containing the *M2* gene sequence was used to generate a 10-fold dilution series of standard concentrations, ranging from  $2.0 \times 10^1$  to  $2.0 \times 10^6$  RNA copies/ $\mu$ l. HMPV quantification was performed in the ABI ViiA7 Real-time PCR System (Applied Biosystems, California, USA).

The linear dynamic range of the HMPV qPCR assay was assessed using a 6- $\log_{10}$  dilution series of HMPV *M2* synthetic oligonucleotide. A standard curve plotted against quantification cycle (Cq) was built using the serial concentration. Linear regression analysis was performed to calculate the PCR efficiency and correlation coefficient based on the standard curve. In order to assess the intra- and inter-assay variability for HMPV viral load quantification, triplicate reactions were performed using a low ( $2.0 \times 10^1$  RNA copies/ $\mu$ l) and moderate ( $2.0 \times 10^3$  RNA copies/ $\mu$ l) standard to determine the mean, standard deviation (SD) and coefficient of variance (CV).

#### Statistical analysis

Demographic (sex, age and ethnicity) and clinical (presence of the eight common cold symptoms and estimated number of days elapsed between symptom onset and enrollment date) characteristics of patients infected by different HMPV genotypes (A and B) and sub-lineages were first assessed using the bivariate analyses (Pearson's chi-square for categorical variables, Independent Samples *t*-test and One-way ANOVA for continuous variables), similar to statistical techniques previously reported [12]. The overall severity of the symptoms was measured

through the summation of eight individual symptom severity score (TSSS), which was modeled as a continuous variable. Association of symptom severity with virological factors (infection by different HMPV genotypes and sub-lineages, and viral load in  $\log_{10}$  RNA copies/ $\mu$ l) and demographic factors was performed using bivariate analyses (Independent Samples *t*-Test, One-way ANOVA, and Pearson's bivariate correlation) and linear regression. Lastly, comparisons of viral load between different periods of enrollment after symptom onset (taking into account the infection by different genotypes/sub-lineages and the differences in demographics and symptom severity profiles) were made using similar analyses mentioned above. A two-sided *p* value lower than 0.05 was considered statistically significant. In order to control false positives in multiple statistical tests such as One-way ANOVA and linear regression, the Bonferroni correction was used to lower the critical *p* value of significance (performed by dividing the critical value by the number of comparisons corresponding to the number of levels in a group) [26]. All analyses were performed using the Statistical Package for Social Sciences version 22.0 (SPSS Inc., New York, USA).


## Results

### Detection and genetic diversity of HMPV

During the study period, a total of 81/3706 (2.2%) nasopharyngeal swab specimens collected were tested positive for HMPV. Among them, only 7/81 (8.6%) specimens were cases of coinfection with other viruses (adenovirus [*n* = 1], enterovirus/rhinovirus [*n* = 3], coronavirus 229E [*n* = 1], influenza A (H3) + enterovirus/rhinovirus [*n* = 1] and influenza B [*n* = 1]). Thus, as coinfection of HMPV viruses was not common in the adult population, we included patients with viral codetection in subsequent analyses and was not considered as another variable in this study. Phylogenetic analysis of the *F* and *G* genes showed that 40/81 (49.4%) of detected HMPV viruses belonged to genotype A whereas 41/81 (50.6%) belonged to genotype B (Fig. 1, Additional file 2). Within genotype A, 25/40 (62.5%) were classified as sub-lineage A2b, whereas 15/40 (37.5%) belonged to a recently described sub-lineage of A2 (designated as unique A2 sub-lineage) [15]. Within genotype B, 25/41 (61.0%) and 16/41 (39.0%) were classified as sub-lineages B1 and B2, respectively.

### Demographic and clinical association with HMPV genetic diversity

Eighty-one outpatients (29 males and 52 females) who were infected by HMPV had an age range of 19 to 86 years old, consisting of adults and elderly (Additional file 2). Among them, 65 patients were grouped as young and middle-age adults (< 65 years old), while 16 patients



**Fig. 1** Phylogenetic analysis of **a**) 85 fusion (F) and **b**) 82 attachment (G) genetic sequences. Maximum-likelihood trees were reconstructed using PAUP version 4.0. The reliability of the branching nodes was assessed by bootstrap analysis of 1000 replicates. Bootstrap values of greater than 70% were indicated on the branch nodes. The generated sequences (dark circles) were named according to the country of isolation (Malaysia, MY), unique sample ID and year of sample collection. Published HMPV reference strains for each genotype/sub-lineage (blue triangles) included A1, NL00-1 (GenBank accession number: AF371337.1), A2a, CAN97-83 (AY297749.1), A2b, JPS03-240.1 (AY530095), B1, NL/1/99 (AY525843.1), and B2, CAN98-75 (AY297748.1). Other published sequences included those from Australia (AUS), Cambodia (CAMB), Canada (CA), India (IND), Japan (JP), Netherlands (NL), Peru (PER), Singapore (SIN), Thailand (TH), United States (USA), and Vietnam (VIET)

were grouped as elderly ( $\geq 65$  years old) (Table 1). The majority of the patients were Malays ( $n = 38$ ), followed by Indians ( $n = 21$ ), Chinese ( $n = 19$ ), and other ethnic groups ( $n = 3$ ). When bivariate analyses were performed, no significant association was observed between HMPV genotypes (A and B) or sub-lineages (A2b, unique A2 sub-lineage, B1, and B2) with the patients' demographics (sex, age, and ethnicity).

The presence of common cold symptoms assessed in this study (sneezing, nasal discharge, nasal congestion, cough, sore throat, hoarseness of voice, muscle ache and headache) was self-reported by the patients. The majority of the patients experienced cough ( $n = 80/81$ , 98.8%) followed by hoarseness of voice ( $n = 72/81$ , 88.9%), while muscle ache and sneezing ( $n = 56/81$ , 69.1%) were the

least experienced by patients, respectively (Table 1). No significant differences were noted in the manifestation of all symptoms between different genotypes or between different sub-lineages. Though, there were noticeably more HMPV genotype B patients ( $n = 31/41$ , 75.6%) that experienced nasal congestion compared to genotype A patients ( $n = 23/40$ , 57.5%) ( $p = 0.084$ ). The estimated number of days elapsed between symptom onset and enrollment date as reported by the patients ranged from 1 day to 2 weeks, where most patients were enrolled after a symptomatic period of 3–5 days ( $n = 36/81$ , 44.4%) (Table 1). While no significant association was found between different enrollment periods after symptom onset and HMPV genotypes or sub-lineages, it was observed that HMPV genotype A-infected patients

**Table 1** Demographic and clinical characteristics of HMPV infection caused by different genotypes and sub-lineages

Characteristics	HMPV Genotype			HMPV Sub-lineage				
	A, $n = 40$	B, $n = 41$	$p$	A2b, $n = 25$	Unique A2 sub-lineage, $n = 15$	B1, $n = 25$	B2, $n = 16$	$p$
Sex								
Male, $n = 29$	13	16	0.540 <sup>b</sup>	8	5	11	5	0.784 <sup>b</sup>
Female, $n = 52$	27	25		17	10	14	11	
Age								
< 65 years old, $n = 65$	32	33	0.956 <sup>b</sup>	20	12	22	11	0.516 <sup>b</sup>
$\geq 65$ years old, $n = 16$	8	8		5	3	3	5	
mean ( $\pm$ SD)	45.28 $\pm$ 18.26	46.15 $\pm$ 20.12	0.839 <sup>a</sup>	44.36 $\pm$ 18.68	46.80 $\pm$ 18.07	44.56 $\pm$ 17.63	48.63 $\pm$ 23.91	0.892 <sup>c</sup>
Ethnicity								
Chinese, $n = 19$	12	7	0.402 <sup>b</sup>	6	6	2	5	0.144 <sup>b</sup>
Malay, $n = 38$	18	20		15	3	14	6	
Indian, $n = 21$	8	13		3	5	9	4	
Others, $n = 3$	2	1		1	1	0	1	
Presence of Symptoms								
Sneezing, $n = 56$	29	27	0.517 <sup>b</sup>	20	9	18	9	0.346 <sup>b</sup>
Nasal congestion, $n = 54$	23	31	0.084 <sup>b</sup>	14	9	21	10	0.166 <sup>b</sup>
Nasal discharge, $n = 58$	31	27	0.245 <sup>b</sup>	20	11	16	11	0.645 <sup>b</sup>
Cough, $n = 80$	40	40	0.320 <sup>b</sup>	25	15	24	16	0.519 <sup>b</sup>
Sore throat, $n = 59$	28	31	0.570 <sup>b</sup>	19	9	21	10	0.282 <sup>b</sup>
Hoarseness of voice, $n = 72$	36	36	0.753 <sup>b</sup>	23	13	23	13	0.680 <sup>b</sup>
Muscle ache, $n = 56$	26	30	0.426 <sup>b</sup>	17	9	18	12	0.812 <sup>b</sup>
Headache, $n = 57$	27	30	0.576 <sup>b</sup>	15	12	18	12	0.541 <sup>b</sup>
Estimated no. of days elapsed between symptom onset and enrollment date								
$\leq 1-2$ days, $n = 20$	9	11	0.207 <sup>b</sup>	5	4	7	4	0.600 <sup>b</sup>
3–5 days, $n = 36$	15	21		11	4	12	9	
$\geq 6$ days, $n = 25$	16	9		9	7	6	3	
mean ( $\pm$ SD)	5.15 $\pm$ 3.63	4.12 $\pm$ 2.55	0.143 <sup>a</sup>	4.56 $\pm$ 2.04	6.13 $\pm$ 5.28	4.20 $\pm$ 2.93	4.00 $\pm$ 1.80	0.211 <sup>c</sup>

*n*: number of patients, *SD*: standard deviation

<sup>a</sup>*p*-value calculated by Independent Samples t-Test

<sup>b</sup>*p*-value calculated by Pearson's Chi-square test

<sup>c</sup>*p*-value calculated by One-way ANOVA

*p* = level of significance (2 tailed) at the 0.05 level

enrolled slightly later after symptom onset ( $5.15 \pm 3.63$  days) compared to genotype B patients ( $4.12 \pm 2.55$  days) ( $p = 0.143$ ).

### Symptom severity of HMPV-infected patients

A greater perceived symptom severity of HMPV-infected patients was indicated by a higher TSSS, which was calculated by the summation of eight individual symptom severity score as reported or assessed during enrollment [20]. Overall, the infected patients had a mean TSSS of  $12.20 \pm 4.58$ , with a range of score from 4 to 23 (maximum score is 24) (Additional file 2), indicating that patients may experience a range of mild to severe respiratory illnesses. When TSSS was compared between different HMPV genotypes and sub-lineages by bivariate and linear regression analyses, no significant differences were observed, even though genotype B patients reported higher TSSS ( $12.85 \pm 4.67$ ) compared to genotype A patients ( $11.53 \pm 4.44$ ), with sub-lineage B1 patients had the highest TSSS ( $13.56 \pm 4.42$ ) among the sub-lineages (Table 2). Also, no significant differences of mean TSSS were observed between different periods of enrollment after symptom onset and no correlation with TSSS was found when the days of enrollment after symptom onset was treated as a continuous variable. The mean TSSS between different sexes and between ethnic groups was not significantly different as well, even though male patients had a higher TSSS compared to female while the Indian ethnic group had the highest TSSS compared to other ethnic groups (Table 2).

In terms of age, mean TSSS was significantly higher in the young and middle-age adults who were < 65 years old ( $12.86 \pm 4.55$ ) as compared to the elderly population who were  $\geq 65$  years old ( $9.50 \pm 3.71$ ) ( $p = 0.008$ ) (Table 2). Moreover, when age was modeled as a continuous variable, it had a significant negative correlation with TSSS ( $r = -0.335$ ,  $p = 0.002$ ). In a simple linear regression model, for the increase of every unit (years) in age, there was a significant decrease of 0.080 unit (score) of TSSS. Thus, our results indicated that age was the only significant predictor of TSSS, with the elderly patients experiencing less severe symptoms than the young and middle-age adults in an outpatient setting. Though, there was no significant difference observed in the estimated enrollment period after symptom onset between patients who were < 65 years old ( $4.58 \pm 3.36$  days) and  $\geq 65$  years old ( $4.81 \pm 2.20$  days) ( $p = 0.797$ ).

### The impact of viral load on symptom severity

The performance of the improved one-step RT-qPCR assay targeting the *M2* gene of HMPV was first evaluated using a 6- $\log_{10}$  dilution series of HMPV *M2* synthetic oligonucleotide standard. The assay produced a typical amplification plot and a standard curve with a

correlation coefficient of 0.999 and amplification efficiency of 96.78%, with a coefficient of determination ( $R^2$ ) of 0.996 (Additional file 3). The intra- and inter-assay variability was estimated within standard range (Additional file 4). Nasopharyngeal viral load in 78/81 HMPV-positive specimens were quantified, with a success rate of 96.5% (Additional file 2). Besides being able to detect all different genotypes and sub-lineages of HMPV, the lowest quantifiable concentration of the assay was estimated at 13 RNA copies/ $\mu\text{l}$ , while the highest viral load recorded in our specimen was 731,917 RNA copies/ $\mu\text{l}$ .

At different periods of enrollment after symptom onset ( $\leq 1-2$  days, 3-5 days, and  $\geq 6$  days), we observed that patients who enrolled in 3-5 days had the highest viral load ( $3.77 \pm 1.20 \log_{10}$  RNA copies/ $\mu\text{l}$ ,  $n = 35$ ) compared to those who enrolled in  $\leq 1-2$  days ( $3.55 \pm 1.53 \log_{10}$  RNA copies/ $\mu\text{l}$ ,  $n = 20$ ) and in  $\geq 6$  days ( $2.93 \pm 1.16 \log_{10}$  RNA copies/ $\mu\text{l}$ ,  $n = 23$ ) after symptom onset (Fig. 2a, Additional file 5). Even though no bivariate association between viral load and periods of enrollment after symptom onset was observed ( $p = 0.052$ ), a post-hoc test using the Bonferroni procedure showed that those who enrolled in 3-5 days had higher viral load ( $p = 0.048$ , insignificant when Bonferroni-corrected  $p < 0.0083$  instead of  $p < 0.05$  was used) compared to those who enrolled in  $\geq 6$  days after symptom onset.

However, the impact of viral load on symptom severity was investigated by performing bivariate correlation between the estimated viral load and TSSS, in which no significant correlation was observed ( $r = -0.118$ ,  $p = 0.303$ ) (Table 2). Taking into account the different periods of enrollment after symptom onset, there was also no significant correlation observed between viral load and TSSS in these periods (Additional file 5). When the patients' TSSS was grouped into three categories with scores that range from 1 to 8, 9-16, and 17-24 to reflect the relative symptom severity of mild, moderate, and severe, respectively [20] (Fig. 2b), no significant differences in viral load between the three categories of symptom severity were observed. Though, among the group of patients with a TSSS of 1-8 (indicative of having milder symptoms) ( $n = 19$ ), those who enrolled  $\geq 6$  days after symptom onset had a significantly lower viral load ( $2.58 \pm 1.07 \log_{10}$  RNA copies/ $\mu\text{l}$ ,  $n = 3$ ) compared to those who enrolled 3-5 days after symptom onset ( $3.99 \pm 0.81 \log_{10}$  RNA copies/ $\mu\text{l}$ ,  $n = 9$ ) ( $p = 0.043$ ), but the difference was insignificant after Bonferroni correction (Fig. 2b, Additional file 5). Overall, our analyses showed that nasopharyngeal viral load could not predict the severity of symptoms caused by HMPV infection, as well as the TSSS scoring system could not predict the amount of viral load in the patient, hence both variables were found to be not correlated in this study.

**Table 2** Assessment of demographical and virological predictors for symptom severity in HMPV-infected patients

Characteristics	TSSS (mean ± SD)	<i>p</i>	$\beta$	<i>p</i> *
HMPV genotype				
A, <i>n</i> = 40	11.53 ± 4.44	0.194 <sup>a</sup>	1.329	0.194
B, <i>n</i> = 41	12.85 ± 4.67		<i>ref.</i>	
HMPV sub-lineage				
A2b, <i>n</i> = 25	11.16 ± 4.12	0.306 <sup>b</sup>	<i>ref.</i>	
Unique A2 sub-lineage, <i>n</i> = 15	12.13 ± 5.03		0.973	0.515
B1, <i>n</i> = 25	13.56 ± 4.42		2.400	0.067
B2, <i>n</i> = 16	11.75 ± 4.99		0.590	0.687
Estimated no. of days elapsed between symptom onset and enrollment date				
<i>r</i> = 0.106		0.348 <sup>c</sup>	0.153	0.348
≤ 1–2 days, <i>n</i> = 20	10.95 ± 4.77	0.373 <sup>b</sup>	– 1.578	0.221
3–5 days, <i>n</i> = 36	12.53 ± 4.35		<i>ref.</i>	
≥ 6 days, <i>n</i> = 25	12.72 ± 4.75		0.192	0.872
Sex				
Male, <i>n</i> = 29	12.41 ± 4.73	0.753 <sup>a</sup>	– 0.337	0.753
Female, <i>n</i> = 52	12.08 ± 4.54		<i>ref.</i>	
Age				
<i>r</i> = –0.335		<b>0.002<sup>c</sup></b>	– 0.080	<b>0.002</b>
< 65 years old, <i>n</i> = 65	12.86 ± 4.55	<b>0.008<sup>a</sup></b>	<i>ref.</i>	
≥ 65 years old, <i>n</i> = 16	9.50 ± 3.71		–3.362	<b>0.008</b>
Ethnicity				
Chinese, <i>n</i> = 19	10.11 ± 4.31	0.054 <sup>b</sup>	– 2.763	0.030#
Malay, <i>n</i> = 38	12.87 ± 4.02		<i>ref.</i>	
Indian, <i>n</i> = 21	13.33 ± 5.25		0.465	0.701
Others, <i>n</i> = 3	9.00 ± 4.36		– 3.868	0.151
Viral Load (log <sub>10</sub> RNA copies/μl), <i>n</i> = 78				
	<i>r</i> = –0.118	0.303 <sup>c</sup>	– 0.206	0.584

TSSS: Total symptom severity score, *n*: number of patients, SD: standard deviation, *ref.* category with the highest number of patients is chosen as reference

<sup>a</sup>*p*-value calculated by Independent Samples t-Test

<sup>b</sup>*p*-value calculated by One-way ANOVA

<sup>c</sup>*p*-value calculated by bivariate correlations

*p*\*: *p*-value calculated by simple linear regression

*r*: Pearson's correlation coefficient

$\beta$ : linear regression coefficient

statistically significant comparisons (*p* < 0.05) are in bold

#*p*-value for significance was adjusted by Bonferroni correction to *p* < 0.0083 (0.05/6)


### Association of viral load with HMPV genetic diversity and demographic factors

By comparing the genetic diversity of HMPV, we observed that after 3–5 days of symptom onset, genotype A patients had a significantly higher viral load ( $4.44 \pm 1.07 \log_{10}$  RNA copies/μl, *n* = 15) compared to genotype B patients ( $3.27 \pm 1.07 \log_{10}$  RNA copies/μl, *n* = 20) (*p* = 0.003) (Fig. 2c, Additional file 5). However, viral load differences between sub-lineages were not significant after Bonferroni correction (*p* = 0.024), though the A2b sub-lineage had a higher viral load ( $4.55 \pm 0.96 \log_{10}$  RNA copies/μl, *n* = 11) compared to B2 ( $3.07 \pm 1.33 \log_{10}$  RNA copies/μl, *n* = 8, *p* = 0.037) sub-lineage during this 3–5 days period (Fig. 2d, Additional file 5). On the

other hand, we also observed that genotype A patients who enrolled ≥6 days had a significantly lower viral load (after Bonferroni correction) compared to those who enrolled 3–5 days after symptom onset (*p* = 0.012, post-hoc test with Bonferroni procedure) (Fig. 2c). Lastly, no significant viral load differences were found between the different demographics (sex, ethnicity, and age) of patients at any of the three periods of enrollment after symptom onset (Additional file 5).

### Discussion

Studies assessing the risk factors such as genetic diversity and viral load that contribute to the burden of illness caused by HMPV infection have generally focused



on high-risk populations such as hospitalized children [27] or adult patients [28], immunocompromised elderly [29], or hematopoietic cell transplant recipients [30], with limited reports from outpatients presenting with acute respiratory tract symptoms. While individuals seeking and receiving outpatient care may not experience severe respiratory complications, their illnesses contribute significantly to the overall disease burden and transmission of the virus to susceptible individuals. The present study investigated the severity of acute respiratory symptoms caused by HMPV infection in a generally adult outpatient population, and assessed the virological and demographical factors that may be associated with the degree of symptom severity.

A standardized four-category scoring of the severity of common cold symptoms has been used as a complementary measure for the impact of respiratory illness in outpatients [16–19]. By summing up the scores of all individual symptoms [20], we could not observe any significant symptom severity differences (or TSSS) between HMPV genotypes/sub-lineages in the adult outpatients (Table 2), suggesting that the genetic diversity of HMPV as shown in this study played limited role as a predictor for the severity of symptoms in the outpatient settings.

Moreover, patients infected with a recently described sub-lineage A2, which was identified based on the estimated genetic distances between sub-lineages in the *F* and *G* genes and was also found in other countries such as China, Vietnam and Cambodia [15], did not show more severe symptoms compared to other sub-lineages. Several previous studies have reported the association of HMPV genetic diversity with disease severity in children. In one report, children infected by genotype A were found to experience more severe acute respiratory illness (based on a scoring method that measures the need for hospitalization, oxygen saturation < 90% at hospital admission, and intensive care unit stay) as compared with genotype B infection [7]. In contrast, a separate study on young children suggested that genotype B infection may result in greater hospitalization rate and higher clinical score (using two scoring methods [7, 31] compared to genotype A [6]. Yet, no significant differences in the severity of illness or clinical manifestation have been reported between HMPV genotypes in children in several other studies [8, 9, 32, 33], which used other scoring methods. The contrasting findings in these studies highlighted that the relationship between HMPV genetic diversity and disease severity remains



undetectable, probably due in part to the lack of a consensus and standardized severity scoring method for outpatients or hospitalized patients. Inclusion of other objective assessment including body temperature, chest X-ray and also respiration rate may help to improve the analysis and reduce discordant findings between studies. In addition, the inconclusive association between HMPV genetic diversity and symptom severity could also be due to the low number of HMPV-positive samples in this study as well as several other studies [7, 9], which may reduce the statistical power for associations [34].

It has been described in several studies that HMPV reinfection can occur during an adult's life due to transient immunity or incomplete protective immune responses for the newly evolved genotype [29, 35], indicating that the elderly individuals are equally susceptible to reinfection. Furthermore, the possible immune dysregulation which lead to a decreased viral clearance in the elderly will further increase their risk of severe symptomatic infection [28] and lead to higher rates of hospitalization [36, 37]. However, unlike previous studies, we found that elderly patients who were  $\geq 65$  years old had less severe symptoms compared to young and adult patients who were  $< 65$  years old. As our study was conducted in the outpatient clinic, it is possible that elderly patients with severe respiratory symptoms may have opted to seek immediate treatment at inpatient settings, leading to sampling bias. Hence, such contrasting observation may be due to the limited sampling on elderly patients who experience more severe symptoms compared to the young and adult patients. Similarly, even though the Indian ethnic group may appear to be experiencing more severe symptoms (based on higher TSSS score) compared to other ethnic groups in this study (Table 2), such observation needs to be interpreted with caution given the limited number of patients in our cohort. Overall, it remains unclear if host demographic factors could be contributing to a more severe symptom outcome in HMPV infection.

The availability of an up-to-date RT-qPCR assay is important for sensitive, specific and rapid detection and quantification of HMPV. Previously, assays for the detection and quantification of HMPV were developed based on limited genome sequences that belonged to the five known genetic lineages/sub-lineages of HMPV: A1, A2 (A2a and A2b sub-lineage), B1 and B2 [37, 38]. Besides, most published assays were designed to target the conserved regions of the nucleoprotein (*N*) gene [39–41] as it is the highly transcribed and conserved gene [24, 42], even though nucleotide mismatches between primer/probe sets with reference sequences have been reported [28, 41, 43, 44]. Thus, in this study, using an updated alignment of complete reference genomes ( $n = 135$ ), primers/probes were designed to target the conserved

region of the *M2* gene with a minimum coverage of 99.3% of the global HMPV sequences (Additional file 1). The viral load in all but three HMPV-positive specimens was successfully captured with the lowest quantifiable concentration estimated at approximately 13 RNA copies/ $\mu\text{L}$ , which was more sensitive than previously published methods [38, 43].

High nasopharyngeal HMPV viral load has been implicated as an important risk factor for severe symptoms in children who were hospitalized [12, 45] or admitted for emergency care [46]. However, in this study, no correlation was observed between viral load and symptom severity in adult outpatients (Table 2, Fig. 2 and Additional file 5). Interestingly, it was found that patients infected with genotype A had a significantly higher peak viral load compared to genotype B-infected patients around 3–5 days of symptom onset, suggesting that genotype A may have a better replication fitness (or replication capacity) and higher transmissibility than genotype B during this period. However, the viral load of genotype A-infected patients who enrolled  $\geq 6$  days were observed to be significantly lower compared those who enrolled 3–5 days after symptom onset, due to the fact they enrolled much later during the course of infection, in which most viruses would have been cleared by immunity. Interestingly, our findings corroborates with a previous report that demonstrated the differences in replication fitness between HMPV genotypes in vitro and in vivo [47]. The study by Aerts et al. showed that HMPV genotype A replicates to a significantly higher titers than genotype B in LLC-MK2 cells and in the lungs of BALB/c mice on day 4 post-infection, but the viral titers of genotype A decreased more rapidly than genotype B after day 4 [47]. As observed in other viral genotypes/serotypes [48, 49], the differences in replication capacity may contribute to the competitive, transmission and epidemiological fitness differences between HMPV genotypes [50], which in turn may dictate the spread and evolution of both genotypes in the human population.

## Conclusions

This study investigated the impact of HMPV genetic diversity and viral load (estimated using an improved quantification assay) on symptom severity in an adult outpatient cohort presenting with acute respiratory tract symptoms, in which both factors were found not to be associated with a more severe symptom outcome. Significant difference in the viral load dynamics between HMPV genotypes A and B was observed during the course of infection due probably to the difference in viral fitness, which may have important implications on virus transmission.

## Additional files

**Additional file 1:** Coverage of newly designed primers set and probe in 135 HMPV genomes. (PDF 229 kb)

**Additional file 2:** Virological, demographical, and clinical information of patients infected with HMPV. (PDF 2165 kb)

**Additional file 3:** A) Amplification plot of one-step RT-qPCR from this study, showing standard concentration of HMPV oligonucleotide of  $2.0 \times 10^6$  genomic copies/ $\mu$ l to  $2.0 \times 10^1$  genomic copies/ $\mu$ l. B) Standard curve showing the amplification efficiency of the assay. (PDF 979 kb)

**Additional file 4:** Intra and inter variability of the improved RT-qPCR assay for HMPV quantification. (PDF 226 kb)

**Additional file 5:** Viral load of HMPV-infected patients at different periods of enrollment after symptom onset (PDF 954 kb)

## Abbreviations

Cq: Quantification cycle; CV: Coefficient of variance; FAM: 6-fluorescein amidite; GTR: General time-reversible; HMPV: Human metapneumovirus; MGB: Minor groove binder; ML: Maximum likelihood; Nfq: Non-fluorescent quencher; RT-qPCR: Reverse transcriptase-quantitative polymerase chain reaction; SD: Standard deviation; TSSS: Total symptom severity score; URTI: Upper respiratory tract infection

## Acknowledgements

We would like to thank Nyoke Pin Wong, Nur Ezreen Syafina and See Wie Teoh for assistance and support.

## Funding

This work was supported by grants from the Ministry of Education, Malaysia: High Impact Research UM.C/625/1/HIR/MOE/CHAN/02/02 and the Postgraduate Research Fund PG084-2015A and PG097-2015A to KKT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

## Availability of data and materials

All data generated or analyzed in this study are included in this article.

## Authors' contributions

Designed experiment: XYO, JBC, KKT; Conducted the experiment: XYO, JBC, KTN, WZC; Analyzed data: XYO, JBC, KTN, WZC, KGC, NSH, YKP, YFC, AK, KKT. All authors read and approved the final manuscript.

## Ethics approval and consent to participate

The study was approved by the University of Malaya Medical Centre (UMMC) Medical Ethics Committee (MEC890.1). Standard, multilingual consent forms permitted by the Medical Ethics Committee were used and written consent was obtained from all study participants. All experiments were performed in accordance with approved guidelines and regulations.

## Consent for publication

We have obtained the written consent from participants to publish the data.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. <sup>2</sup>School of Healthcare and Medical Sciences, Sunway University, 47500 Kuala Lumpur, Selangor, Malaysia. <sup>3</sup>Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, 50603 Kuala Lumpur, Malaysia. <sup>4</sup>Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. <sup>5</sup>Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.

Received: 5 November 2017 Accepted: 16 May 2018

Published online: 23 May 2018

## References

- Afonso CL, Amarasinghe GK, Bányai K, Bao Y, Basler CF, Bavari S, et al. Taxonomy of the order Mononegavirales: update 2016. *Arch Virol*. 2016;161:2351–60.
- van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. *Nat Med*. 2001;7:719–24.
- Haas LE, Thijsen SF, Van Elden L, Heemstra KA. Human metapneumovirus in adults. *Viruses*. 2013;5:87–110.
- van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL, et al. Antigenic and genetic variability of human metapneumoviruses. *Emerg Infect Dis*. 2004;10:658–66.
- Papenburg J, Hamelin MÈ, Ouhoumane N, Carbonneau J, Ouakki M, Raymond F, et al. Comparison of risk factors for human metapneumovirus and respiratory syncytial virus disease severity in young children. *J Infect Dis*. 2012;206:178–89.
- Pitoiset C, Darniot M, Huet F, Aho SL, Pothier P, Manoha C. Human metapneumovirus genotypes and severity of disease in young children (n = 100) during a 7-year study in Dijon hospital, France. *J Med Virol*. 2010;82:1782–9.
- Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Differences in clinical severity between genotype a and genotype B human metapneumovirus infection in children. *Clin Infect Dis*. 2006;42:e111–3.
- Agapov E, Sumino KC, Gaudreault-Keener M, Storch GA, Holtzman MJ. Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness. *J Infect Dis*. 2006;193:396–403.
- Xiao NG, Xie ZP, Zhang B, Yuan XH, Song JR, Gao HC, et al. Prevalence and clinical and molecular characterization of human metapneumovirus in children with acute respiratory infection in China. *Pediatr Infect Dis J*. 2010;29:131–4.
- Al-Turab M, Chehadeh W, Al-Nakib W. Phylogenetic analysis of human metapneumovirus detected in hospitalized patients in Kuwait during the years 2009–2011. *J Infect Public Health*. 2015;8:448–57.
- Al-Turab M, Chehadeh W, Al-Mulia F, Al-Nakib W. Human metapneumovirus in patients with respiratory tract infection in Kuwait. *J Med Virol*. 2011;83:1811–7.
- Roussy JF, Carbonneau J, Ouakki M, Papenburg J, Hamelin MÈ, De Serres G, et al. Human metapneumovirus viral load is an important risk factor for disease severity in young children. *J Clin Virol*. 2014;60:133–40.
- Jagušić M, Slović A, Ljubin-Sternak S, Mlinarić-Galinović G, Forčić D. Genetic diversity of human metapneumovirus in hospitalized children with acute respiratory infections in Croatia. *J Med Virol*. 2017;89:1885–93.
- Neemuchwala A, Duvvuri VR, Marchand-Austin A, Li A, Gubbay JB. Human metapneumovirus prevalence and molecular epidemiology in respiratory outbreaks in Ontario, Canada. *J Med Virol*. 2015;87:269–74.
- Chow WZ, Chan YF, Oong XY, Ng LJ, SS NE, Ng KT, et al. Genetic diversity, seasonality and transmission network of human metapneumovirus: identification of a unique sub-lineage of the fusion and attachment genes. *Sci Rep*. 2016;6:27730.
- Zitter JN, Mazonson PD, Miller DP, Hulley SB, Balmes JR. Aircraft cabin air recirculation and symptoms of the common cold. *JAMA*. 2002;288:483–6.
- Yale SH, Liu K. Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. *Arch Intern Med*. 2004;164:1237–41.
- Jackson GG, Dowling HF, Spiesman IG, Boand AV. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. *AMA Arch Intern Med*. 1958;101:267–78.

19. Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, St George R, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. *JAMA*. 1999;281:1797–804.
20. VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. *BMC Infect Dis*. 2014;14:231.
21. Loens K, Bergs K, Ursi D, Goossens H, Ieven M. Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens. *J Clin Microbiol*. 2007;45:421–5.
22. Pabbaraju K, Wong S, Tokaryk KL, Fonseca K, Drews SJ. Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. *J Clin Microbiol*. 2011;49:1738–44.
23. Swofford DL. PAUP\* : phylogenetic analysis using parsimony (\*and other methods), version 4. Sunderland, MA, USA: Sinauer Associates; 2003.
24. de Graaf M, Osterhaus AD, Fouchier RA, Holmes EC. Evolutionary dynamics of human and avian metapneumoviruses. *J Gen Virol*. 2008;89:2933–42.
25. Katoh K, Asimenos G, Toh H. Multiple alignment of DNA sequences with MAFFT. *Methods Mol Biol*. 2009;537:39–64.
26. Dunn OJ. Multiple comparisons among means. *J Am Stat Assoc*. 1961;56:52–64.
27. Gerna G, Campanini G, Rovida F, Sarasini A, Lilleri D, Paolucci S, et al. Changing circulation rate of human metapneumovirus strains and types among hospitalized pediatric patients during three consecutive winter-spring seasons. *Arch Virol*. 2005;150:2365–75.
28. Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. *Arch Intern Med*. 2008;168:2489–96.
29. Falsey AR, Erdman D, Anderson LJ, Walsh EE. Human metapneumovirus infections in young and elderly adults. *J Infect Dis*. 2003;187:785–90.
30. Huck B, Egger M, Bertz H, Peyerl-Hoffman G, Kern WV, Neumann-Haefelin D, et al. Human metapneumovirus infection in a hematopoietic stem cell transplant recipient with relapsed multiple myeloma and rapidly progressing lung cancer. *J Clin Microbiol*. 2006;44:2300–3.
31. Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. *J Infect Dis*. 2002;186:839–42.
32. Wei HY, Tsao KC, Huang CG, Huang YC, Lin TY. Clinical features of different genotypes/genogroups of human metapneumovirus in hospitalized children. *J Microbiol Immunol Infect*. 2013;46:352–7.
33. Debur MC, Vidal LR, Stroparo E, Nogueira MB, Almeida SM, Takahashi GA, et al. Impact of human metapneumovirus infection on in and outpatients for the years 2006–2008 in southern Brazil. *Mem Institut Oswaldo Cruz*. 2010;105:1010–8.
34. Cohen J. Statistical power analysis. *Curr Dir Psychol Sci*. 1992;1:98–101.
35. Boivin G, De Serres G, Hamelin ME, Côté S, Argouin M, Tremblay G, et al. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. *Clin Infect Dis*. 2007;44:1152–8.
36. Widmer K, Zhu Y, Williams JV. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. *J Infect Dis*. 2012;206:56–62.
37. Falsey AR, Hennessey PA, Formica MA, Criddle MM, Bear JM, Walsh EE. Humoral immunity to human metapneumovirus infection in adults. *Vaccine*. 2010;28:1477–80.
38. Choudhary ML, Anand SP, Sonawane NS, Chadha MS. Development of real-time RT-PCR for detection of human metapneumovirus and genetic analysis of circulating strains (2009–2011) in Pune, India. *Arch Virol*. 2014;159:217–25.
39. Côté S, Abed Y, Boivin G. Comparative evaluation of real-time PCR assays for detection of the human metapneumovirus. *J Clin Microbiol*. 2003;41:3631–5.
40. Mackay JM, Jacob KC, Woolhouse D, Waller K, Symmis MW, Whitley DM, et al. Molecular assays for detection of human metapneumovirus. *J Clin Microbiol*. 2003;41:100–5.
41. Maertzdorf J, Wang CK, Brown JB, Quinto JD, Chu M, de Graaf M, et al. Real-time reverse transcriptase PCR assay for detection of human metapneumoviruses from all known genetic lineages. *J Clin Microbiol*. 2004;42:981–6.
42. Collins PL, Wertz GW. cDNA cloning and transcriptional mapping of nine polyadenylated RNAs encoded by the genome of human respiratory syncytial virus. *Proc Natl Acad Sci*. 1983;80:3208–12.
43. Klemenc J, Asad Ali S, Johnson M, Tollefson SJ, Talbot HK, Hartert TV, et al. Real-time reverse transcriptase PCR assay for improved detection of human metapneumovirus. *J Clin Virol*. 2012;54:371–5.
44. Kodani M, Yang G, Conklin LM, Travis TC, Whitney CG, Anderson LJ, et al. Application of TaqMan® low density arrays for simultaneous detection of multiple respiratory pathogens. *J Clin Microbiol*. 2011;49:2175–82.
45. Martin ET, Kuypers J, Heugel J, Englund JA. Clinical disease and viral load in children infected with respiratory syncytial virus or human metapneumovirus. *Diagn Microbiol Infect Dis*. 2008;62:382–8.
46. Bosis S, Esposito S, Osterhaus AD, Tremolati E, Begliatti E, Tagliabue C, et al. Association between high nasopharyngeal viral load and disease severity in children with human metapneumovirus infection. *J Clin Virol*. 2008;42:286–90.
47. Aerts L, Cavanagh MH, Dubois J, Carbonneau J, Rhéaume C, Lavigne S, et al. Effect of in vitro syncytium formation on the severity of human metapneumovirus disease in a murine model. *PLoS One*. 2015;10:e0120283.
48. Ariën KK, Abrahams A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. *J Virol*. 2005;79:8979–90.
49. Schaap-Nutt A, Liesman R, Bartlett EJ, Scull MA, Collins PL, Pickles RJ, et al. Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium. *Virology*. 2012;433:320–8.
50. Wargo AR, Kurath G. Viral fitness: definitions, measurement, and current insights. *Curr Opin Virol*. 2012;2:538–45.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://www.biomedcentral.com/submissions)

